Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials

Ed Moran; Tim Cook; Anna L. Goodman; Ravindra K. Gupta; Stephen Jolles; David K. Menon; David J. Roberts; Sinisa Savic; Manu Shankar-Hari; Michael Brown; David M. Lowe

doi:10.1016/S1473-3099(21)00464-3

Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials

Ed Moran, Tim Cook, Anna L. Goodman, Ravindra K. Gupta, Stephen Jolles, David K. Menon, David J. Roberts, Sinisa Savic, Manu Shankar-Hari, Michael Brown, David M. Lowe

Research output: Contribution to journal › Comment/debate

24 Citations (Scopus)

Original language	English
Pages (from-to)	1345-1347
Number of pages	3
Journal	The Lancet Infectious Diseases
Volume	21
Issue number	10
DOIs	https://doi.org/10.1016/S1473-3099(21)00464-3
Publication status	Published - Oct 2021
Externally published	Yes

Bibliographical note

Funding Information:
ALG reports grants from Novavax to run vaccine trials and non-commercial funding from the INSIGHT network (NIH-TICO trial) to her institution outside of the submitted work; ALG is also named as an inventor on a patent issued to the University of Oxford covering use of a promotor construct incorporated in the ChAdOx1 nCoV-19 vaccine developed by AstraZeneca and the University of Oxford. RKG reports personal fees from GlaxoSmithKline, Johnson & Johnson, and UMOVIS Lab, and a research grant from Invisi Smart Technologies, outside of the submitted work. SJ reports grants from CSL Behring and Takeda and personal fees from CSL Behring, Octapharma, Pharming, Takeda, LFB, Grifols, Biotest, and UCB pharma, outside of the submitted work; SJ also served on advisory boards for CSL Behring, Octapharma, Pharming, LFB, Grifols, and Biotest, and on data and safety monitoring boards for Biotest and UCB Pharma, outside of the submitted work. DKM served as one of the principal investigators for the UK Convalescent Plasma Trial in critically ill patients with COVID-19, conducted as part of the REMAP-CAP Trial. MS-H reports a grant from the National Institute for Health Research (NIHR Clinician Scientist Fellowship; NIHR-CS–2016-16-011), during the conduct of the study, and served as Clinical Lead for the UK Convalescent Plasma Trial in critically ill patients with COVID-19, conducted as part of the REMAP-CAP Trial. DML reports non-financial support (travel and subsistence costs) from CSL Behring, personal fees from Merck, and grants from LifeArc, the British Society for Antimicrobial Chemotherapy, Blood Cancer UK, Bristol Myers Squibb, and the UK Medical Research Council, outside of the submitted work. All other authors declare no competing interests.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1473-3099(21)00464-3

Cite this

@article{bfeea59b2cdc4e0093a52167de12ab2b,

title = "Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials",

author = "Ed Moran and Tim Cook and Goodman, {Anna L.} and Gupta, {Ravindra K.} and Stephen Jolles and Menon, {David K.} and Roberts, {David J.} and Sinisa Savic and Manu Shankar-Hari and Michael Brown and Lowe, {David M.}",

note = "Funding Information: ALG reports grants from Novavax to run vaccine trials and non-commercial funding from the INSIGHT network (NIH-TICO trial) to her institution outside of the submitted work; ALG is also named as an inventor on a patent issued to the University of Oxford covering use of a promotor construct incorporated in the ChAdOx1 nCoV-19 vaccine developed by AstraZeneca and the University of Oxford. RKG reports personal fees from GlaxoSmithKline, Johnson & Johnson, and UMOVIS Lab, and a research grant from Invisi Smart Technologies, outside of the submitted work. SJ reports grants from CSL Behring and Takeda and personal fees from CSL Behring, Octapharma, Pharming, Takeda, LFB, Grifols, Biotest, and UCB pharma, outside of the submitted work; SJ also served on advisory boards for CSL Behring, Octapharma, Pharming, LFB, Grifols, and Biotest, and on data and safety monitoring boards for Biotest and UCB Pharma, outside of the submitted work. DKM served as one of the principal investigators for the UK Convalescent Plasma Trial in critically ill patients with COVID-19, conducted as part of the REMAP-CAP Trial. MS-H reports a grant from the National Institute for Health Research (NIHR Clinician Scientist Fellowship; NIHR-CS–2016-16-011), during the conduct of the study, and served as Clinical Lead for the UK Convalescent Plasma Trial in critically ill patients with COVID-19, conducted as part of the REMAP-CAP Trial. DML reports non-financial support (travel and subsistence costs) from CSL Behring, personal fees from Merck, and grants from LifeArc, the British Society for Antimicrobial Chemotherapy, Blood Cancer UK, Bristol Myers Squibb, and the UK Medical Research Council, outside of the submitted work. All other authors declare no competing interests.",

year = "2021",

month = oct,

doi = "10.1016/S1473-3099(21)00464-3",

language = "English",

volume = "21",

pages = "1345--1347",

journal = "The Lancet Infectious Diseases",

issn = "1473-3099",

publisher = "Elsevier",

number = "10",

}

TY - JOUR

T1 - Persistent SARS-CoV-2 infection

T2 - the urgent need for access to treatment and trials

AU - Moran, Ed

AU - Cook, Tim

AU - Goodman, Anna L.

AU - Gupta, Ravindra K.

AU - Jolles, Stephen

AU - Menon, David K.

AU - Roberts, David J.

AU - Savic, Sinisa

AU - Shankar-Hari, Manu

AU - Brown, Michael

AU - Lowe, David M.

N1 - Funding Information: ALG reports grants from Novavax to run vaccine trials and non-commercial funding from the INSIGHT network (NIH-TICO trial) to her institution outside of the submitted work; ALG is also named as an inventor on a patent issued to the University of Oxford covering use of a promotor construct incorporated in the ChAdOx1 nCoV-19 vaccine developed by AstraZeneca and the University of Oxford. RKG reports personal fees from GlaxoSmithKline, Johnson & Johnson, and UMOVIS Lab, and a research grant from Invisi Smart Technologies, outside of the submitted work. SJ reports grants from CSL Behring and Takeda and personal fees from CSL Behring, Octapharma, Pharming, Takeda, LFB, Grifols, Biotest, and UCB pharma, outside of the submitted work; SJ also served on advisory boards for CSL Behring, Octapharma, Pharming, LFB, Grifols, and Biotest, and on data and safety monitoring boards for Biotest and UCB Pharma, outside of the submitted work. DKM served as one of the principal investigators for the UK Convalescent Plasma Trial in critically ill patients with COVID-19, conducted as part of the REMAP-CAP Trial. MS-H reports a grant from the National Institute for Health Research (NIHR Clinician Scientist Fellowship; NIHR-CS–2016-16-011), during the conduct of the study, and served as Clinical Lead for the UK Convalescent Plasma Trial in critically ill patients with COVID-19, conducted as part of the REMAP-CAP Trial. DML reports non-financial support (travel and subsistence costs) from CSL Behring, personal fees from Merck, and grants from LifeArc, the British Society for Antimicrobial Chemotherapy, Blood Cancer UK, Bristol Myers Squibb, and the UK Medical Research Council, outside of the submitted work. All other authors declare no competing interests.

PY - 2021/10

Y1 - 2021/10

UR - http://www.scopus.com/inward/record.url?scp=85115355853&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(21)00464-3

DO - 10.1016/S1473-3099(21)00464-3

M3 - Comment/debate

C2 - 34411531

AN - SCOPUS:85115355853

SN - 1473-3099

VL - 21

SP - 1345

EP - 1347

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

IS - 10

ER -

Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials

Bibliographical note

UN SDGs

Access to Document

Other files and links

Cite this